Events & Presentations
Date | Event Details | Remind Me |
---|---|---|
Apr 3 - Apr 4, 2023
|
7th Complement UK Training Course and Symposium
|
Date | Event Details |
---|---|
Sep 14, 2022 3:30 PM EDT
|
Morgan Stanley 20th Annual Global Healthcare Conference
Note: Presentation Cancelled Type: Fireside chat presentation |
Sep 13, 2022 4:20 PM EDT
|
Baird 2022 Global Healthcare Conference
Type: Fireside chat presentation
Presenter: Christopher Anzalone, Ph.D., President and CEO, Arrowhead Pharmaceuticals |
Sep 12 - Sep 14, 2022
|
H.C. Wainwright 24th Annual Global Investment Conference – September 12-14, 2022
Type: Fireside chat presentation
Presenter: Christopher Anzalone, Ph.D., President and CEO, Arrowhead Pharmaceuticals |
Sep 7 - Sep 9, 2022
|
2022 Wells Fargo Healthcare Conference
Type: Investor meetings
Presenter: Vincent Anzalone, CFA, Vice President Finance and Investor Relations, Arrowhead Pharmaceuticals |
Sep 4 - Sep 6, 2022
|
European Respiratory Society (ERS) International Congress 2022
View Presentation 2.5 MB
Title: Silencing MMP7 expression with a lung-targeted RNAi molecule limits fibrosis and preserves pulmonary function in bleomycin-injured rats |
Aug 4, 2022 4:30 PM EDT
|
Arrowhead Pharmaceuticals 2022 Third Quarter Results
Prepared Remarks 241.8 KB
|
Jun 22 - Jun 26, 2022
|
The International Liver Congress™ 2022 - The Annual Meeting of the European Association for the Study of the Liver (EASL)
EASL 2022 AROAAT2002 1.5 MB
EASL 2022 JNJ-3989 MIDD 11.8 MB
EASL 2022 JNJ-3989 REEF-1 4.1 MB
EASL 2022 JNJ-3989 REEF-2 1.2 MB
Title: Effects of the siRNA JNJ-3989 and/or the Capsid Assembly Modulator JNJ-6379 on Viral Markers of Chronic Hepatitis B: Results From the REEF-1 Study Title: Understanding the Dynamics of HBsAg Decline Through Model-informed Drug Development (MIDD) of siRNA and CAM-N for the Treatment of Chronic Hepatitis B (CHB) Virus Infection Title: Efficacy and Safety of Finite 48-week Treatment With the siRNA JNJ-3989 and the Capsid Assembly Modulator JNJ-6379 in HBeAg Negative Virologically Suppressed Chronic Hepatitis B Patients: Results from the REEF-2 Study Title: Reduction of Intra-hepatic Z-AAT Synthesis by Fazirsiran Decreases Globule Burden and Improves Histological Measures of Liver Disease in Adults with Alpha-1 Antitrypsin Deficiency |
Jun 13 - Jun 16, 2022
|
Goldman Sachs 43rd Annual Global Healthcare Conference
Type: Fireside chat presentation
Presenter: Vincent Anzalone, Vice President Finance and Investor Relations, Arrowhead Pharmaceuticals |
Jun 8, 2022 8:30 AM EDT
|
Jefferies Healthcare Conference
Type: Fireside chat presentation
Presenter: Vincent Anzalone, Vice President Finance and Investor Relations, Arrowhead Pharmaceuticals |
May 26, 2022 10:00 AM EDT
|
Pulmonary R&D Day
View Presentation 16.6 MB
New York
|